Table of Contents
ISRN Neurology
Volume 2013, Article ID 370943, 6 pages
http://dx.doi.org/10.1155/2013/370943
Clinical Study

The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial

1Department of Neurology, University Medical Center Groningen, University of Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands
2Department of Neurology, Rijnstate Hospital, Postbus 9555, 6800 TA Arnhem, The Netherlands
3Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
4Department of Neurology, Center for Neurosciences, University Hospital Brussels, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Brussels, Belgium

Received 19 March 2013; Accepted 16 April 2013

Academic Editors: D. E. Bulman, C.-M. Chen, G. Meco, and D. Schiffer

Copyright © 2013 Jop Mostert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Koch, J. Mostert, D. Heersema, and J. De Keyser, “Progression in multiple sclerosis: further evidence of an age dependent process,” Journal of the Neurological Sciences, vol. 255, no. 1-2, pp. 35–41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Panitch, “Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study,” Neurology, vol. 63, no. 10, pp. 1788–1795, 2004. View at Google Scholar · View at Scopus
  3. J. S. Wolinsky, P. A. Narayana, P. O'Connor et al., “Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial,” Annals of Neurology, vol. 61, no. 1, pp. 14–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. I. Rojas, M. Romano, A. Ciapponi, L. Patrucco, and E. Cristiano, “Interferon beta for primary progressive multiple sclerosis,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD006643, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. K. G. Su, G. Banker, D. Bourdette, and M. Forte, “Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis,” Current Neurology and Neuroscience Reports, vol. 9, no. 5, pp. 411–417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Stadelmann, M. Kerschensteiner, T. Misgeld, W. Brück, R. Hohlfeld, and H. Lassmann, “BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?” Brain, vol. 125, no. 1, pp. 75–85, 2002. View at Google Scholar · View at Scopus
  7. R. Srinivasan, N. Sailasuta, R. Hurd, S. Nelson, and D. Pelletier, “Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T,” Brain, vol. 128, no. 5, pp. 1016–1025, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. H. M. Sickmann, A. B. Walls, A. Schousboe, S. D. Bouman, and H. S. Waagepetersen, “Functional significance of brain glycogen in sustaining glutamatergic neurotransmission,” Journal of Neurochemistry, vol. 109, supplement 1, pp. 80–86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Brown, S. B. Tekkök, and B. R. Ransom, “Glycogen regulation and functional role in mouse white matter,” Journal of Physiology, vol. 549, no. 2, pp. 501–512, 2003. View at Google Scholar · View at Scopus
  10. J. De Keyser, E. Zeinstra, J. Mostert, and N. Wilczak, “β2-Adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis,” Trends in Pharmacological Sciences, vol. 25, no. 2, pp. 67–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. De Keyser, N. Wilczak, R. Leta, and C. Streetland, “Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors,” Neurology, vol. 53, no. 8, pp. 1628–1633, 1999. View at Google Scholar · View at Scopus
  12. E. K. C. Kong, L. Peng, Y. Chen, A. C. H. Yu, and L. Hertz, “Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration,” Neurochemical Research, vol. 27, no. 1-2, pp. 113–120, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Allaman, H. Fiumelli, P. J. Magistretti, and J. L. Martin, “Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes,” Psychopharmacology, vol. 216, no. 1, pp. 75–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. Mostert, P. E. Sijens, M. Oudkerk, and J. De Keyser, “Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis,” Neuroscience Letters, vol. 402, no. 1-2, pp. 22–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Mostert, F. Admiraal-Behloul, J. M. Hoogduin et al., “Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 9, pp. 1027–1031, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  18. A. Beck, R. A. Steer, and G. K. Brown, Manual for Beck Depression Inventory-2, Psychological Corporation, San Antonio, Tex, USA, 1996.
  19. G. R. Cutter, M. L. Baier, R. A. Rudick et al., “Development of a multiple sclerosis functional composite as a clinical trial outcome measure,” Brain, vol. 122, no. 5, pp. 871–882, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. S. L. Hauser, D. M. Dawson, and J. R. Lehrich, “Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH,” The New England Journal of Medicine, vol. 308, no. 4, pp. 173–180, 1983. View at Google Scholar · View at Scopus
  21. A. J. Dittner, S. C. Wessely, and R. G. Brown, “The assessment of fatigue: a practical guide for clinicians and researchers,” Journal of Psychosomatic Research, vol. 56, no. 2, pp. 157–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Sharrack and R. A. C. Hughes, “The Guy's neurological disability scale (GNDS): a new disability measure for multiple sclerosis,” Multiple Sclerosis, vol. 5, no. 4, pp. 223–233, 1999. View at Google Scholar · View at Scopus
  23. J. E. Ware Jr., “SF-36 Health Survey update,” Spine, vol. 25, no. 24, pp. 3130–3139, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Smith, M. Jenkinson, M. W. Woolrich et al., “Advances in functional and structural MR image analysis and implementation as FSL,” NeuroImage, vol. 23, supplement 1, pp. S208–S219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Admiraal-Behloul, D. M. J. Van Den Heuvel, H. Olofsen et al., “Fully automatic segmentation of white matter hyperintensities in MR images of the elderly,” NeuroImage, vol. 28, no. 3, pp. 607–617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. S. Fischer, A. J. Jack, J. E. Knicker, and R. A. Rudick, Cutter G Administration and Scoring Manual for the Multiple Sclerosis Functional Composite Measure (MSFC), Demos, 1999.
  27. D. E. Goodkin, R. A. Rudick, S. VanderBrug Medendorp et al., “Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis,” Annals of Neurology, vol. 37, no. 1, pp. 30–40, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. R. G. Schlienger, L. M. Fischer, H. Jick, and C. R. Meier, “Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction,” Drug Safety, vol. 27, no. 14, pp. 1157–1165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. L. V. A. E. Bosma, J. J. Kragt, L. Brieva et al., “The search for responsive clinical endpoints in primary progressive multiple sclerosis,” Multiple Sclerosis, vol. 15, no. 6, pp. 715–720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. S. Chung, Y. C. Chung, E. Bok et al., “Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress,” Brain Research, vol. 1363, pp. 143–150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. I. H. Li, W. S. Huang, C. Y. Shiue et al., “Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET,” NeuroImage, vol. 49, no. 2, pp. 1259–1270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. C. M. Lim, S. W. Kim, J. Y. Park, C. Kim, S. H. Yoon, and J. K. Lee, “Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect,” Journal of Neuroscience Research, vol. 87, no. 4, pp. 1037–1045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Chollet, J. Tardy, J. F. Albucher et al., “Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial,” The Lancet Neurology, vol. 10, no. 2, pp. 123–130, 2011. View at Publisher · View at Google Scholar · View at Scopus